
CRISPR Therapeutics AG
NASDAQ:CRSP

Intrinsic Value
The intrinsic value of one
CRSP
stock under the Base Case scenario is
60.24
USD.
Compared to the current market price of 37.82 USD,
CRISPR Therapeutics AG
is
Undervalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
CRISPR Therapeutics AG
Fundamental Analysis


Revenue & Expenses Breakdown
CRISPR Therapeutics AG
Balance Sheet Decomposition
CRISPR Therapeutics AG
Current Assets | 1.9B |
Cash & Short-Term Investments | 1.9B |
Receivables | 25m |
Other Current Assets | 8.3m |
Non-Current Assets | 304.9m |
PP&E | 277.6m |
Other Non-Current Assets | 27.3m |
Free Cash Flow Analysis
CRISPR Therapeutics AG
USD | |
Free Cash Flow | USD |
Earnings Waterfall
CRISPR Therapeutics AG
Revenue
|
37.3m
USD
|
Operating Expenses
|
-503.9m
USD
|
Operating Income
|
-466.6m
USD
|
Other Expenses
|
100.3m
USD
|
Net Income
|
-366.3m
USD
|
CRSP Profitability Score
Profitability Due Diligence
CRISPR Therapeutics AG's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

Score
CRISPR Therapeutics AG's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
CRSP Solvency Score
Solvency Due Diligence
CRISPR Therapeutics AG's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Score
CRISPR Therapeutics AG's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRSP Price Targets Summary
CRISPR Therapeutics AG
According to Wall Street analysts, the average 1-year price target for
CRSP
is 82.24 USD
with a low forecast of 32.32 USD and a high forecast of 281.4 USD.
Dividends
Current shareholder yield for CRSP is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CRSP
stock under the Base Case scenario is
60.24
USD.
Compared to the current market price of 37.82 USD,
CRISPR Therapeutics AG
is
Undervalued by 37%.